Cantor Fitzgerald Reiterates Overweight Rating on BridgeBio Pharma (BBIO), Updates Estimates

August 11, 2026 9:44 AM

Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and $110.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found